Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease: CVD-REAL Study

被引：0
|
作者：
Cavender, Matthew A.
Norhammar, Anna
Birkeland, Kare I.
Jorgensen, Marit Eika
Wilding, John P. H.
Khunti, Kamlesh
Fu, Alex Z.
Bodegard, Johan
Blak, Betina T.
Wittbrodt, Eric T.
Thuresson, Marcus
Fenici, Peter
Hammar, Niklas
Kosiborod, Mikhail N.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
377-OR
引用
收藏
页码：A99 / A100
页数：2
相关论文
共 50 条
  • [21] Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
    Kosiborod, Mikhail
    Lam, Carolyn S. P.
    Kohsaka, Shun
    Kim, Dae Jung
    Karasik, Avraham
    Shaw, Jonathan
    Tangri, Navdeep
    Goh, Su-Yen
    Thuresson, Marcus
    Chen, Hungta
    Surmont, Filip
    Hammar, Niklas
    Fenici, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (23) : 2628 - 2639
  • [22] Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
    Cheng, Judy W. M.
    Colucci, Vincent
    Kalus, James S.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 252 - 260
  • [23] Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
    Gager, Gloria M. M.
    Gelbenegger, Georg
    Jilma, Bernd
    von Lewinski, Dirk
    Sourij, Harald
    Eyileten, Ceren
    Filipiak, Krzysztof
    Postula, Marek
    Siller-Matula, Jolanta M. M.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [24] Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    Lisenby, Katelin M.
    Osmonson, Alyssa
    PHARMACOTHERAPY, 2021, 41 (06): : 526 - 536
  • [25] Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis
    Gager, G. M.
    Gelbenegger, G.
    Jilma, B.
    Von Lewinski, D.
    Sourij, H.
    Eyileten, C.
    Filipiak, K.
    Postula, M.
    Hengstenberg, C.
    Siller-Matula, J.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1051 - 1051
  • [26] Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 Inhibitors-Analysis from the CVD-REAL 2 Study
    Kohsaka, Shun
    Lam, Carolyn S.
    Kim, Dae Jung
    Karasik, Avraham
    Tangri, Navdeep
    Goh, Su-Yen
    Thuresson, Marcus
    Chen, Hungta
    Surmont, Filip
    Hammar, Niklas
    Fenici, Peter
    Kosiborod, Mikhail
    DIABETES, 2018, 67
  • [27] SGLT2 inhibitors and vericiguat in real-world patients admitted for worsening heart failure
    Tarantini, R.
    Acone, L.
    Alonge, S.
    Catagnano, F.
    Foti, M.
    Oldani, M.
    Mortara, A.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [28] SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
    Tarantini, R.
    Vecchi, A. L.
    Matteo, F.
    De Ponti, R.
    Mortara, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 779 - 779
  • [29] Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
    Hacil, A.
    Hanon, O.
    Vidal, J.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [30] The effect of SGLT2 inhibitors treatment on left ventricular function and heart failure hospitalization in heart failure patients with reduce ejection fraction: A retrospective study
    Ramli, S. A. S.
    Ismail, A. F.
    Isa, W. Y. H. W.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
12345